TR200202544T2 - Torasemid'in yeni polimorfu V - Google Patents

Torasemid'in yeni polimorfu V

Info

Publication number
TR200202544T2
TR200202544T2 TR2002/02544T TR200202544T TR200202544T2 TR 200202544 T2 TR200202544 T2 TR 200202544T2 TR 2002/02544 T TR2002/02544 T TR 2002/02544T TR 200202544 T TR200202544 T TR 200202544T TR 200202544 T2 TR200202544 T2 TR 200202544T2
Authority
TR
Turkey
Prior art keywords
torasemide
new polymorph
torasemid
preparation
modifications
Prior art date
Application number
TR2002/02544T
Other languages
English (en)
Inventor
Filic Darko
Dumic Miljenko
Klepic Bozena
Danilovski Aleksandar
Tudja Marijan
Original Assignee
Pliva Farmaceutska Industrija, Dionicko Drustvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska Industrija, Dionicko Drustvo filed Critical Pliva Farmaceutska Industrija, Dionicko Drustvo
Publication of TR200202544T2 publication Critical patent/TR200202544T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bulus torasemid'in yeni bir polimorf (çok sekilli) V'i ile, bunun hazirlanmasi için olan bir islem ile, torasemid'in kristal haldeki I ve III modifikasyonlarinin hazirlanmasi için ham madde olarak bunun kullanilmasi ile, amorf (sekilsiz) torasemid modifikasyonlari ile ve torasemid'in farmasötik olarak kabul edilebilir tuzlari ile, aktif madde olarak torasemid'in söz konusu yeni polimorf V'ini içeren farmasötik biçimleri ile, hem de bunun kullanimi ile ilgilidir.
TR2002/02544T 2000-05-19 2000-09-25 Torasemid'in yeni polimorfu V TR200202544T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20000328A HRP20000328A2 (en) 2000-05-19 2000-05-19 Novel polymorph v of torasemide

Publications (1)

Publication Number Publication Date
TR200202544T2 true TR200202544T2 (tr) 2003-03-21

Family

ID=10947111

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/02544T TR200202544T2 (tr) 2000-05-19 2000-09-25 Torasemid'in yeni polimorfu V

Country Status (32)

Country Link
US (2) US7241782B1 (tr)
EP (1) EP1283828B1 (tr)
JP (1) JP2003533512A (tr)
KR (1) KR20030016267A (tr)
CN (1) CN1520403A (tr)
AP (1) AP2002002679A0 (tr)
AR (1) AR028840A1 (tr)
AT (1) ATE342890T1 (tr)
AU (1) AU2000274381A1 (tr)
BG (1) BG107407A (tr)
BR (1) BR0015877A (tr)
CA (1) CA2409699A1 (tr)
CZ (1) CZ20024104A3 (tr)
DE (1) DE60031450T2 (tr)
DZ (1) DZ3356A1 (tr)
EA (1) EA005003B1 (tr)
EE (1) EE200200637A (tr)
GE (1) GEP20043321B (tr)
HR (1) HRP20000328A2 (tr)
HU (1) HUP0302135A2 (tr)
IL (1) IL152810A0 (tr)
IS (1) IS6620A (tr)
MA (1) MA25748A1 (tr)
MX (1) MXPA02011402A (tr)
NO (1) NO20025509L (tr)
NZ (1) NZ522544A (tr)
PL (1) PL358257A1 (tr)
SK (1) SK17712002A3 (tr)
TR (1) TR200202544T2 (tr)
WO (1) WO2001087841A1 (tr)
YU (1) YU84202A (tr)
ZA (1) ZA200209181B (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781461C (en) * 1999-08-11 2006-02-23 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
IN192178B (tr) 2001-08-03 2004-03-06 Ranbaxy Lab
US7067385B2 (en) * 2003-09-04 2006-06-27 Micron Technology, Inc. Support for vertically oriented capacitors during the formation of a semiconductor device
CN1824647B (zh) * 2005-02-22 2011-04-20 田边三菱制药株式会社 (±)2-(二甲基氨基)-1-{[O-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
IN182496B (tr) * 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto

Also Published As

Publication number Publication date
IS6620A (is) 2002-11-14
NO20025509D0 (no) 2002-11-15
EA005003B1 (ru) 2004-10-28
EA200201236A1 (ru) 2003-04-24
AP2002002679A0 (en) 2002-12-31
BR0015877A (pt) 2003-04-29
NO20025509L (no) 2002-11-15
YU84202A (sh) 2006-05-25
CZ20024104A3 (cs) 2003-04-16
AR028840A1 (es) 2003-05-28
EP1283828B1 (en) 2006-10-18
HRP20000328A2 (en) 2002-02-28
MXPA02011402A (es) 2003-06-06
DZ3356A1 (en) 2001-11-22
GEP20043321B (en) 2004-04-13
DE60031450D1 (de) 2006-11-30
ATE342890T1 (de) 2006-11-15
EP1283828A1 (en) 2003-02-19
PL358257A1 (en) 2004-08-09
US7241782B1 (en) 2007-07-10
NZ522544A (en) 2004-07-30
SK17712002A3 (sk) 2003-05-02
HUP0302135A2 (hu) 2003-10-28
CA2409699A1 (en) 2001-11-22
JP2003533512A (ja) 2003-11-11
BG107407A (en) 2004-01-30
KR20030016267A (ko) 2003-02-26
CN1520403A (zh) 2004-08-11
IL152810A0 (en) 2003-06-24
ZA200209181B (en) 2004-02-12
US20070238759A1 (en) 2007-10-11
EE200200637A (et) 2004-04-15
AU2000274381A1 (en) 2001-11-26
MA25748A1 (fr) 2003-04-01
DE60031450T2 (de) 2007-09-20
WO2001087841A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
NO20025719D0 (no) Nye triazolpyrimidinforbindelser
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
DE60217118D1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
ES2179318T3 (es) Derivados de acido cinamico y su uso como antagonistas de integrina.
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
TR200202544T2 (tr) Torasemid'in yeni polimorfu V
NZ510898A (en) Crystal modification N of torasemide
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
TR200100286T2 (tr) (1H)-Benzo[C]kuinolizin-3-on türevlerinin sentezi için proses.
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
YU70502A (sh) Amorfna modifikacija torasemida
PT1292303E (pt) Formulacao farmaceutica estavel compreendendo modificacao de torsemida ii
JPS646245A (en) Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient
AR016070A1 (es) Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein
TR200101388T2 (tr) Yeni pirimidin türevleri ve bunları hazırlama prosesleri
PT1272495E (pt) Processo para a preparacao de cefoperazona de sodio altamente cristalina
TR200302026T4 (tr) (2S)-aminoindan türevleri, hazırlanmaları için bir işlem ve seçici dopamin D3 ligandları olarak kullanımları.
TR199900013T2 (tr) Yeni bilesikler.
ES8708213A1 (es) Un procedimiento para preparar un derivado de 1-benzhidril--4-cinamilpiperazina
NO20004075L (no) Substituerte pyrimidin-2-yloksy-karboksylsyrederivater, fremstilling av disse og deres anvendelse som endotelin- antagonister
EP1346985A4 (en) PYRIMIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
JPS53149985A (en) Preparation of 5-fluorouracil derivatives
ES465221A1 (es) Procedimiento para la preparacion de nuevos derivados de 4- ter-buti-3'-clorodifenilamina con actividad antihistaminica.
BR0105022A (pt) Método para preparação de citalopram, métodos para preparação de compostos utilizados na preparação do mesmo, citalopram e sua composição farmacêutica